PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19141712-0	2009	Transport of lamivudine [(-)-beta-L-2",3"-dideoxy-3"-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.	Lamivudine	13-23	solute carrier family 22 member 1	Homo sapiens	155-194	
23917312-10	2013	In particular, TB patients with coexisting HIV or diabetes might experience significant DDIs in situations of coadministration of ethambutol and clinical therapeutics known to be hOCT1/hOCT3 substrates (e.g., lamivudine or metformin).	Lamivudine	209-219	solute carrier family 22 member 1	Homo sapiens	179-184	
22415520-0	2012	Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.	Lamivudine	86-96	solute carrier family 22 member 1	Homo sapiens	20-48	
22415520-0	2012	Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.	Lamivudine	86-96	solute carrier family 22 member 1	Homo sapiens	50-54	
22415520-2	2012	When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT.	Lamivudine	31-41	solute carrier family 22 member 1	Homo sapiens	75-79	
22415520-2	2012	When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT.	Lamivudine	31-41	solute carrier family 22 member 1	Homo sapiens	170-174	
22415520-2	2012	When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT.	Lamivudine	31-41	solute carrier family 22 member 1	Homo sapiens	79-84	
22415520-2	2012	When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT.	Lamivudine	31-41	solute carrier family 22 member 1	Homo sapiens	170-174	
22415520-2	2012	When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT.	Lamivudine	140-150	solute carrier family 22 member 1	Homo sapiens	170-174	
22415520-2	2012	When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT.	Lamivudine	140-150	solute carrier family 22 member 1	Homo sapiens	170-174	
22415520-3	2012	The Clint of lamivudine in oocytes expressing OCT1-P283L was decreased by 85.1% compared with OCT1-WT, whereas it was decreased by 48.7% in oocytes expressing OCT1-P341L.	Lamivudine	13-23	solute carrier family 22 member 1	Homo sapiens	46-50	
22415520-3	2012	The Clint of lamivudine in oocytes expressing OCT1-P283L was decreased by 85.1% compared with OCT1-WT, whereas it was decreased by 48.7% in oocytes expressing OCT1-P341L.	Lamivudine	13-23	solute carrier family 22 member 1	Homo sapiens	94-98	
22415520-3	2012	The Clint of lamivudine in oocytes expressing OCT1-P283L was decreased by 85.1% compared with OCT1-WT, whereas it was decreased by 48.7% in oocytes expressing OCT1-P341L.	Lamivudine	13-23	solute carrier family 22 member 1	Homo sapiens	94-98	
22415520-5	2012	When comparing various substrates such as MPP+, TEA, metformin and lamivudine, the effects of the OCT1 genetic polymorphisms on their uptake were not identical.	Lamivudine	67-77	solute carrier family 22 member 1	Homo sapiens	98-102	
22415520-7	2012	In conclusion, the effect of genetic variations of OCT1 and OCT2 on the uptake of MPP+, TEA, metformin and lamivudine was substrate-dependent.	Lamivudine	107-117	solute carrier family 22 member 1	Homo sapiens	51-55	
27445813-0	2016	Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.	Lamivudine	68-78	solute carrier family 22 member 1	Homo sapiens	14-42	
18490433-7	2008	Substrates with highest transport efficacy (V(max)/K(m)) were lamivudine (OCT1, 8 microl/mg protein/min; OCT2, 4.4 microl/mg protein/min) and zalcitabine (OCT1, 4.1 microl/mg protein/min; OCT2, 2.6 microl/mg protein/min).	Lamivudine	62-72	solute carrier family 22 member 1	Homo sapiens	74-78	
27445813-0	2016	Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.	Lamivudine	68-78	solute carrier family 22 member 1	Homo sapiens	44-49	
27445813-0	2016	Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.	Lamivudine	80-83	solute carrier family 22 member 1	Homo sapiens	14-42	
27445813-0	2016	Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.	Lamivudine	80-83	solute carrier family 22 member 1	Homo sapiens	44-49	
25914645-9	2015	Tetraethylammonium accumulation was higher in SLC22A1-expressing cells compared to mock-transfected cells (10.6 +- 0.8 muM vs. 0.3 +- 0.004 muM, p = 0.009) and was significantly reduced in SLC22A1-expressing cells when co-incubated with all antiretrovirals tested except atazanavir, lamivudine, tenofovir, zidovudine, and raltegravir.	Lamivudine	283-293	solute carrier family 22 member 1	Homo sapiens	46-53